Emerging therapies in cystic fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 4, Issue 3, 2010, Pages 177-185

  Anderson, Paula ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

aerosol drug therapy; cystic fibrosis; cystic fibrosis transmembrane conductance regulator; investigational therapies

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; AMIKACIN; ARIKACE; ATALUREN; AZTREONAM; BRAMITOB; CAYSTON; COLISTIMETHATE; COLISTIN; COLOBREATHE; DENUFOSOL; DURAMYCIN; GENE THERAPY AGENT; GLUCOCORTICOID; GS 9411; HYDROXYCHLOROQUINE; IBUPROFEN; ION CHANNEL; MANNITOL; MESSENGER RNA; PARVOVIRUS VECTOR; PIOGLITAZONE; PLACEBO; SILDENAFIL; SIMVASTATIN; SODIUM CHLORIDE COTRANSPORTER; SPI 8811; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 770; VX 809;

ANTIINFLAMMATORY ACTIVITY; BRONCHOSPASM; CHROMOSOME 7; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRY POWDER; EPITHELIUM CELL; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE THERAPY; HUMAN; LIFE EXPECTANCY; LUNG FUNCTION; NONHUMAN; NONSENSE MUTATION; PATHOPHYSIOLOGY; POWDER INHALER; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOP CODON;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIFE EXPECTANCY;

EID: 77953328174     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465810371107     Document Type: Review

References (40)

1. Ashlock, M.A., Beall, R.J., Hamblett, N.M., Konstan, M.W., Penland, C.M., Ramsey, B.W. et al. (2009) A pipeline of therapies for cystic fibrosis. Semin Respir Crit Care Med 30: 611-626.
2. Boyle, M.J. ( 2007) Adult cystic fibrosis. J Am Med Assoc 298: 1787-1793.
3. Chuchalin, A., Csiszer, E., Byurkovics, K., Bartinicka, M.T., Sands, D., Kaproanov, N. et al. (2007) A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 9(Suppl 1): 21-31.
4. Clancy, J.P. ( 2009) Clinical trials of lipid-associated aerosolized amikacin: the ArikaceTM story (abstract). Pediatr Pulmonol 32(Suppl): 186-187.
5. Clancy, J.P., Rowe, S.M., Durie, P., Freedman, S., Dong, Q., Ordonez, C. et al. (2009) NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator (abstract). Pediatr Pulmonol 32(Suppl): 288.
6. Cystic Fibrosis Foundation (2009) Cystic Fibrosis Foundation Patient Registry 208 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation.
7. Donaldson, S.H., Bennett, W.D., Zeman, K.L., Knowles, M.R., Tarran, R. and Boucher, R.C. ( 2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241-250.
8. Eigen, J., Rosenstein, B.J., Fitzsimmons, S. and Schidlow, D.V. ( 1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 126: 515-523.
9. Elkins, M., Robinson, M., Rose, B., Harbour, C., Moriarty, C., Marks, G. et al. (2006) National hypertonic saline in cystic fibrosis (NHSCF) study group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
10. Fiel, S.B. ( 2008) Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Rev Resp Med 2: 479-487.
11. Flume, P.A., O'sullivan, B.P., Robinson, K.A., Goss, C.H., Mogayzel, P.J., Willey-Courand, D.B. et al. (2007) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176: 957-969.
12. Griesenbach, U., Geddes, D.M. and Alton, E.W. ( 2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13: 1061-1067.
13. Hirawat, S., Welch, E.M., Elfring, G.L., Northcutt, V.J., Paushkin, S., Hwang, S. et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430-444.
14. Jacques, A., Daviskas, E., Turton, J.A., McKay, K., Cooper, P., Stirling, R.G. et al. (2008) Inhaled mannitol improves lung function in cystic fibrosis. Chest 133: 1388-1396.
15. Kellerman, D., Mospan, A.R., Engels, J., Schaberg, A., Gorden, J. and Smiley, L. ( 2008) Denufosol: a review of studies with inhaled P2Y2 agonists that led to phase 3. Pulm Pharmacol Ther 21: 600-607.
16. Kerem, E., Bauer, S., Strauss, P., Jaffe, N., Armoni, S., Pugatsch, T. et al. (2009) Safety and efficacy of inhaled human alpha-1 antitrypsin in CF: a report of a phase II clinical study. Pediatr Pulmonol 32(Suppl): 303 (abstract).
17. Kerem, B., Chiba-Falek, O. and Kerem, E. ( 1997) Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1: 35-39.
18. Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M. et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727.
19. Konstan, M.W., Byard, P.J., Hoppel, C.I. and Davis, P.B. ( 1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: 848-854.
20. Kunzelmann, K. and Mall, M. ( 2003) Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2: 299-309.
21. Lands, L.C., Milner, R., Cantin, A.M., Manson, D. and Corey, M. ( 2007) High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151: 249-254.
22. Li, Z., Zhang, Y., Wurtz, W., Lee, J.K., Malinin, V.S., Durwas-Krishnan, S. et al. (2008) Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 21: 245-254.
23. Lommatzsch, S.T. and Aris, R. (2009) Genetics of cystic fibrosis. Semin Respir Crit Care Med 30: 531-538.
24. Lubamba, B., Lecourt, H., Lebacq, J., Lebecque, P., De Jonge, H., Wallemacq, P. et al. (2008) Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Resp Crit Care Med 177: 506-515.
25. Machen, T.E. ( 2006) Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol 291: C218-C230.
26. Martin, S.L., Downey, D., Bilton, D., Keogan, M.R., Edgar, J. and Elborn, J.S. ( 2006) Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 41: 177-183.
27. McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z. and Montgomery, A.B. ( 2008) Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 178: 921-928.
28. Moss, R.B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P.L., Clancy, J.P. et al. (2007) Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gen Ther 18: 726-732.
29. O'sullivan, B.P. and Freedman, S.D. ( 2009) Cystic fibrosis. Lancet 373: 1891-1904.
30. Pickles, R.J. ( 2004) Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc 1: 302-308.
31. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J. et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340: 23-30.
32. Ratjen, F.A. ( 2006) Restoring airway surface liquid in cystic fibrosis. N Engl J Med 354: 291-293.
33. Ratjen, F.A. (2009) Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 54: 595-602.
34. Retsch-Bogart, G.Z., Quittner, A.L., Gibson, R.L., Oermann, C.M., McCoy, K.S., Montgomery, A.B. et al. (2009) Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135: 1223-1232.
35. Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z. et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
36. Rowe, S.M., Miller, S. and Sorscher, E.J. ( 2005) Cystic fibrosis. N Engl J Med 352: 1992-2001.
37. Sly, P.D., Brennan, S., Gangell, C., de Klerk, N., Murray, C., Mott, L. et al. (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 180: 146-152.
38. Tirouvanziam, R., Conrad, C.K., Bottiglieri, T., Herzenberg, L.A., Moss, R.B. and Herzenberg, L.A. ( 2006) High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 103: 4628-4633.
39. Tirouvanziam, R., de Bentzmann, S., Hubeau, C., Hinnrasky, J., Hinnrasky, J., Jacquot, J. et al. (2000) Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 23: 121-127.
40. Wills, P.J. ( 2007) Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs 16: 1121-1126.